Jeffery W Kelly

List of Publications by Year
in descending order

162	19,064	14655 66	12272 133
papers	citations	h-index	g-index

170	170	170	13781
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biological and Chemical Approaches to Diseases of Proteostasis Deficiency. Annual Review of Biochemistry, 2009, 78, 959-991.	11.1	1,035
2	The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Current Opinion in Structural Biology, 1998, 8, 101-106.	5.7	992
3	Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology, 2012, 79, 785-792.	1.1	658
4	Alternative conformations of amyloidogenic proteins govern their behavior. Current Opinion in Structural Biology, 1996, 6, 11-17.	5.7	601
5	Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9629-9634.	7.1	582
6	Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2872-2891.	2.8	573
7	Repurposing Diflunisal for Familial Amyloid Polyneuropathy. JAMA - Journal of the American Medical Association, 2013, 310, 2658.	7.4	551
8	The Acid-Mediated Denaturation Pathway of Transthyretin Yields a Conformational Intermediate That Can Self-Assemble into Amyloid. Biochemistry, 1996, 35, 6470-6482.	2.5	547
9	Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry, 1992, 31, 8654-8660.	2.5	521
10	Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics. Science, 2003, 299, 713-716.	12.6	491
11	Stress-Independent Activation of XBP1s and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments. Cell Reports, 2013, 3, 1279-1292.	6.4	436
12	The Biological and Chemical Basis for Tissue-Selective Amyloid Disease. Cell, 2005, 121, 73-85.	28.9	427
13	Targeting protein aggregation for the treatment of degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 759-780.	46.4	338
14	Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2817-2822.	7.1	336
15	Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16427-16432.	7.1	320
16	Transthyretin Aggregation under Partially Denaturing Conditions Is a Downhill Polymerizationâ€. Biochemistry, 2004, 43, 7365-7381.	2.5	303
17	The folding mechanism of a Î²-sheet: the WW domain. Journal of Molecular Biology, 2001, 311, 373-393.	4.2	297
18	Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Journal of Neurology, 2013, 260, 2802-2814.	3.6	284

#	Article	IF	Citations
19	Trans -Suppression of Misfolding in an Amyloid Disease. Science, 2001, 293, 2459-2462.	12.6	282
20	The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug. Journal of Molecular Biology, 2012, 421, 185-203.	4.2	267
21	Context-dependent contributions of backbone hydrogen bonding to Î²-sheet folding energetics. Nature, 2004, 430, 101-105.	27.8	260
22	Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 236-249.	3.0	236
23	An Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denaturedâ€. Biochemistry, 2001, 40, 11442-11452.	2.5	219
24	Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue. Journal of the American Chemical Society, 2016, 138, 7353-7364.	13.7	212
25	Tenosynovial and Cardiac Amyloidosis inÂPatients Undergoing CarpalÂTunnelÂRelease. Journal of the American College of Cardiology, 2018, 72, 2040-2050.	2.8	209
26	Characterization of the Transthyretin Acid Denaturation Pathways by Analytical Ultracentrifugation:Â Implications for Wild-Type, V30M, and L55P Amyloid Fibril Formationâ€. Biochemistry, 1998, 37, 17851-17864.	2.5	207
27	The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3131-3136.	7.1	206
28	â€œInverse Drug Discoveryâ€•Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates. Journal of the American Chemical Society, 2018, 140, 200-210.	13.7	206
29	Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, Evaluation, and Mechanism of Action. Angewandte Chemie - International Edition, 2003, 42, 2758-2761.	13.8	204
30	Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry, 1993, 32, 12119-12127.	2.5	200
31	Structure-function-folding relationship in a WW domain. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10648-10653.	7.1	199
32	Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Laboratory Investigation, 2004, 84, 545-552.	3.7	186
33	Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. ELife, 2016, 5, .	6.0	185
34	The Most Pathogenic Transthyretin Variant, L55P, Forms Amyloid Fibrils under Acidic Conditions and Protofilaments under Physiological Conditionsâ€. Biochemistry, 1999, 38, 13560-13573.	2.5	179
35	Localized thermodynamic coupling between hydrogen bonding and microenvironment polarity substantially stabilizes proteins. Nature Structural and Molecular Biology, 2009, 16, 684-690.	8.2	178
36	The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nature Chemical Biology, 2014, 10, 902-910.	8.0	166

#	Article	IF	Citations
37	Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current Opinion in Structural Biology, 2010, 20, 54-62.	5.7	160
38	Protein Native-State Stabilization by Placing Aromatic Side Chains in N-Glycosylated Reverse Turns. Science, 2011, 331, 571-575.	12.6	157
39	Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase:â€‰ Identification of the Transmembrane Domain as a Site for Oligomerization. Biochemistry, 1998, 37, 15177-15187.	2.5	149
40	The Pathway by Which the Tetrameric Protein Transthyretin Dissociatesâ€. Biochemistry, 2005, 44, 15525-15533.	2.5	149
41	Pharmacologic ATF6 activation confers global protection in widespread disease models by reprograming cellular proteostasis. Nature Communications, 2019, 10, 187.	12.8	140
42	WW: An isolated threeâ€stranded antiparallel Î²â€sheet domain that unfolds and refolds reversibly; evidence for a structured hydrophobic cluster in urea and GdnHCl and a disordered thermal unfolded state. Protein Science, 1999, 8, 841-853.	7.6	137
43	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	3.2	124
44	A glimpse of a possible amyloidogenic intermediate of transthyretin. Nature Structural Biology, 2000, 7, 754-757.	9.7	121
45	AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9992-9997.	7.1	120
46	Mechanisms of Transthyretin Inhibition of Î²-Amyloid AggregationIn Vitro. Journal of Neuroscience, 2013, 33, 19423-19433.	3.6	118
47	Quantification of the Thermodynamically Linked Quaternary and Tertiary Structural Stabilities of Transthyretin and Its Disease-Associated Variants: The Relationship between Stability and Amyloidosis. Biochemistry, 2008, 47, 6969-6984.	2.5	115
48	Unfolded protein responseâ€induced <scp>ER</scp> dj3 secretion links <scp>ER</scp> stress to extracellular proteostasis. EMBO Journal, 2015, 34, 4-19.	7.8	110
49	Amyloid as a natural product. Journal of Cell Biology, 2003, 161, 461-462.	5.2	109
50	A chemical approach to elucidate tin mechanism of transthyretin and Î²-protein amyloid fibril formation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 186-205.	3.0	108
51	Toward Assessing the Position-Dependent Contributions of Backbone Hydrogen Bonding to Î²-Sheet Folding Thermodynamics Employing Amide-to-Ester Perturbations. Journal of the American Chemical Society, 2004, 126, 16762-16771.	13.7	107
52	Determinants for Dephosphorylation of the RNA Polymerase II C-Terminal Domain by Scp1. Molecular Cell, 2006, 24, 759-770.	9.7	103
53	Guanidine Hydrochloride-Induced Denaturation and Refolding of Transthyretin Exhibits a Marked Hysteresis:Â Equilibria with High Kinetic Barriersâ€. Biochemistry, 1997, 36, 10230-10239.	2.5	101
54	Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Science, 2001, 10, 1606-1613.	7.6	99

#	Article	IF	Citations
55	Evaluating Î²-turn mimics as Î²-sheet folding nucleators. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11067-11072.	7.1	97
56	Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nature Chemical Biology, 2020, 16, 1052-1061.	8.0	90
57	A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans. Journal of the American Chemical Society, 2015, 137, 7404-7414.	13.7	86
58	Structural and Energetic Basis of Carbohydrateâ€“Aromatic Packing Interactions in Proteins. Journal of the American Chemical Society, 2013, 135, 9877-9884.	13.7	85
59	Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery. Nature Chemistry, 2020, 12, 906-913.	13.6	85
60	Pharmacologic ATF6 activating compounds are metabolically activated to selectively modify endoplasmic reticulum proteins. ELife, 2018, 7, .	6.0	85
61	Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13046-13051.	7.1	83
62	Structure-based design and analysis of SuFEx chemical probes. RSC Medicinal Chemistry, 2020, 11, 10-17.	3.9	83
63	Anion Shielding of Electrostatic Repulsions in Transthyretin Modulates Stability and Amyloidosis:â€‰Insight into the Chaotrope Unfolding Dichotomy. Biochemistry, 2001, 40, 11453-11459.	2.5	80
64	Characterization of the Structure and Function of W â†' F WW Domain Variants:Â Identification of a Natively Unfolded Protein That Folds upon Ligand Bindingâ€. Biochemistry, 1999, 38, 14338-14351.	2.5	79
65	Kinetic Stabilization of the Native State by Protein Engineering: Implications for Inhibition of Transthyretin Amyloidogenesis. Journal of Molecular Biology, 2005, 347, 841-854.	4.2	73
66	Structural Insight into pH-Induced Conformational Changes within the Native Human Transthyretin Tetramer. Journal of Molecular Biology, 2008, 382, 1157-1167.	4.2	70
67	NMR solution structure of the isolated Apo Pin1 WW domain: Comparison to the x-ray crystal structures of Pin1. Biopolymers, 2002, 63, 111-121.	2.4	69
68	Context-Dependent Effects of Asparagine Glycosylation on Pin WW Folding Kinetics and Thermodynamics. Journal of the American Chemical Society, 2010, 132, 15359-15367.	13.7	69
69	The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. Journal of Molecular Biology, 2016, 428, 4280-4297.	4.2	66
70	Localized Structural Fluctuations Promote Amyloidogenic Conformations in Transthyretin. Journal of Molecular Biology, 2013, 425, 977-988.	4.2	65
71	Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface 1 1Edited by P. E. Wright. Journal of Molecular Biology, 2000, 303, 555-565.	4.2	64
72	Nucleated Antiparallel Î²-Sheet That Folds and Undergoes Self-Assembly:Â A Template Promoted Folding Strategy toward Controlled Molecular Architectures. Macromolecules, 1996, 29, 355-366.	4.8	63

#	Article	IF	Citations
73	Sequence determinants of thermodynamic stability in a WW domainâ€"An allâ€Îˆ²â€sheet protein. Protein Science, 2009, 18, 1806-1813.	7.6	63
74	ERdj3 Is an Endoplasmic Reticulum Degradation Factor for Mutant Glucocerebrosidase Variants Linked to Gaucherâ€™s Disease. Chemistry and Biology, 2014, 21, 967-976.	6.0	63
75	Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange. Biochemistry, 2014, 53, 1993-2006.	2.5	62
76	Glycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contexts. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14127-14132.	7.1	61
77	Backboneâ€"Backbone Hâ€Bonds Make Contextâ€Dependent Contributions to Protein Folding Kinetics and Thermodynamics: Lessons from Amideâ€toâ€Ester Mutations. Advances in Protein Chemistry, 2005, 72, 39-78.	4.4	60
78	Kinetic Stabilization of an Oligomeric Protein under Physiological Conditions Demonstrated by a Lack of Subunit Exchange:â€‰ Implications for Transthyretin Amyloidosis. Biochemistry, 2005, 44, 9265-9274.	2.5	58
79	Nâ€glycosylation of enhanced aromatic sequons to increase glycoprotein stability. Biopolymers, 2012, 98, 195-211.	2.4	58
80	Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimerâ€™s Disease-like Pathology. Cell Reports, 2017, 21, 2614-2627.	6.4	56
81	The unfolded protein response regulator ATF6 promotes mesodermal differentiation. Science Signaling, 2018, 11, .	3.6	54
82	Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight, 2019, 4, .	5.0	53
83	Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8360-8369.	7.1	52
84	Synthesis of a Negatively Charged Dibenzofuran-Based Î²-Turn Mimetic and Its Incorporation into the WW Miniprotein-Enhanced Solubility without a Loss of Thermodynamic Stability. Journal of the American Chemical Society, 2002, 124, 11900-11907.	13.7	46
85	A Stilbene That Binds Selectively to Transthyretin in Cells and Remains Dark until It Undergoes a Chemoselective Reaction To Create a Bright Blue Fluorescent Conjugate. Journal of the American Chemical Society, 2010, 132, 16043-16051.	13.7	45
86	Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 854-863.	7.1	45
87	Increasing protein stability using a rational approach combining sequence homology and structural alignment: Stabilizing the WW domain. Protein Science, 2008, 10, 1454-1465.	7.6	44
88	The Dependence of Carbohydrateâ€"Aromatic Interaction Strengths on the Structure of the Carbohydrate. Journal of the American Chemical Society, 2016, 138, 7636-7648.	13.7	44
89	Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Science Translational Medicine, 2017, 9, .	12.4	44
90	Synthesis of Sulfotyrosineâ€Containing Peptides by Incorporating Fluorosulfated Tyrosine Using an Fmocâ€Based Solidâ€Phase Strategy. Angewandte Chemie - International Edition, 2016, 55, 1835-1838.	13.8	43

#	Article	IF	Citations
91	Native State Hydrogen Exchange Study of Suppressor and Pathogenic Variants of Transthyretin. Journal of Molecular Biology, 2002, 320, 821-832.	4.2	41
92	Stabilizing the C_H2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon. ACS Chemical Biology, 2016, 11, 1852-1861.	3.4	40
93	Individual and Collective Contributions of Chaperoning and Degradation to Protein Homeostasis in E.Âcoli. Cell Reports, 2015, 11, 321-333.	6.4	39
94	Improving mass spectrometric sequencing of arginine-containing peptides by derivatization with acetylacetone. , 1997, 32, 1337-1349.		38
95	Amide-to-E-Olefin versus Amide-to-Ester Backbone H-Bond Perturbations:Â Evaluating the Oâ‹¯O Repulsion for Extracting H-Bond Energies. Journal of the American Chemical Society, 2006, 128, 15948-15949.	13.7	38
96	Toward quantification of protein backboneâ€“backbone hydrogen bonding energies: An energetic analysis of an amideâ€toâ€ester mutation in an Î±â€helix within a protein. Protein Science, 2008, 17, 1096-1101.	7.6	38
97	Structural Changes Associated with Transthyretin Misfolding and Amyloid Formation Revealed by Solution and Solid-State NMR. Biochemistry, 2016, 55, 1941-1944.	2.5	38
98	The endoplasmic reticulum <scp>HSP</scp>40 coâ€chaperone <scp>ER</scp>dj3/<scp>DNAJB</scp>11 assembles and functions as a tetramer. EMBO Journal, 2017, 36, 2296-2309.	7.8	38
99	Fluorescence Turn-On Folding Sensor To Monitor Proteome Stress in Live Cells. Journal of the American Chemical Society, 2015, 137, 11303-11311.	13.7	37
100	Enhanced Aromatic Sequons Increase Oligosaccharyltransferase Glycosylation Efficiency and Glycan Homogeneity. Chemistry and Biology, 2015, 22, 1052-1062.	6.0	36
101	Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors. Chemical Communications, 2013, 49, 9188.	4.1	35
102	Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA. Journal of Cystic Fibrosis, 2020, 19, 733-741.	0.7	35
103	Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 175-180.	3.0	34
104	Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 120-128.	3.0	33
105	Dissecting the Structure, Thermodynamic Stability, and Aggregation Properties of the A25T Transthyretin (A25T-TTR) Variant Involved in Leptomeningeal Amyloidosis: Identifying Protein Partners That Co-Aggregate during A25T-TTR Fibrillogenesis in Cerebrospinal Fluid. Biochemistry, 2011, 50, 11070-11083.	2.5	31
106	A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin. Bioorganic and Medicinal Chemistry, 2011, 19, 1505-1514.	3.0	31
107	ATF6 is essential for human cone photoreceptor development. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	31
108	NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations. Biochemistry, 2018, 57, 4421-4430.	2.5	30

#	Article	IF	Citations
109	Endoplasmic Reticulum Proteostasis Influences the Oligomeric State of an Amyloidogenic Protein Secreted from Mammalian Cells. Cell Chemical Biology, 2016, 23, 1282-1293.	5.2	29
110	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy, 2021, Volume 15, 1225-1243.	4.3	29
111	Quantitative Interactome Proteomics Reveals a Molecular Basis for ATF6-Dependent Regulation of a Destabilized Amyloidogenic Protein. Cell Chemical Biology, 2019, 26, 913-925.e4.	5.2	26
112	Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?. Biochemistry, 2017, 56, 6597-6614.	2.5	26
113	Attacking Amyloid. New England Journal of Medicine, 2005, 352, 722-723.	27.0	25
114	Solid-State NMR Studies Reveal Native-like Î²-Sheet Structures in Transthyretin Amyloid. Biochemistry, 2016, 55, 5272-5278.	2.5	25
115	Pharmacologic Approaches for Adapting Proteostasis in the Secretory Pathway to Ameliorate Protein Conformational Diseases. Cold Spring Harbor Perspectives in Biology, 2020, 12, a034108.	5.5	25
116	The Role of Protein Thermodynamics and Primary Structure in Fibrillogenesis of Variable Domains from Immunoglobulin Light Chains. Journal of the American Chemical Society, 2019, 141, 13562-13571.	13.7	24
117	Genetic ablation of Nâ€linked glycosylation reveals two key folding pathways for R345W fibulinâ€3, a secreted protein associated with retinal degeneration. FASEB Journal, 2015, 29, 565-575.	0.5	23
118	Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7710-E7719.	7.1	23
119	Deducing the presence of proteins and proteoforms in quantitative proteomics. Nature Communications, 2018, 9, 2320.	12.8	23
120	Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures. Theranostics, 2016, 6, 1792-1809.	10.0	22
121	Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 24-29.	3.0	22
122	Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation. Current Opinion in Structural Biology, 2022, 72, 267-278.	5.7	21
123	High-Resolution Mapping of the Folding Transition State of a WW Domain. Journal of Molecular Biology, 2016, 428, 1617-1636.	4.2	20
124	Pathogenic Mutations Induce Partial Structural Changes in the Native Î²-Sheet Structure of Transthyretin and Accelerate Aggregation. Biochemistry, 2017, 56, 4808-4818.	2.5	20
125	Residues Comprising the Enhanced Aromatic Sequon Influence Protein N-Glycosylation Efficiency. Journal of the American Chemical Society, 2017, 139, 12947-12955.	13.7	20
126	A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Current Opinion in Chemical Biology, 2016, 32, 10-21.	6.1	19

#	Article	IF	Citations
127	Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. Biochemistry, 2020, 59, 2319-2327.	2.5	19
128	Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Advances, 2021, 5, 1037-1049.	5.2	19
129	Using Cooperatively Folded Peptides To Measure Interaction Energies and Conformational Propensities. Accounts of Chemical Research, 2017, 50, 1875-1882.	15.6	18
130	Synthesis of Sulfotyrosineâ€Containing Peptides by Incorporating Fluorosulfated Tyrosine Using an Fmocâ€Based Solidâ€Phase Strategy. Angewandte Chemie, 2016, 128, 1867-1870.	2.0	17
131	Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. Journal of Medicinal Chemistry, 2021, 64, 6273-6299.	6.4	16
132	Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis. Journal of Neurology, 2018, 265, 299-307.	3.6	16
133	Metabolically Activated Proteostasis Regulators Protect against Glutamate Toxicity by Activating NRF2. ACS Chemical Biology, 2021, 16, 2852-2863.	3.4	16
134	Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127356.	2.2	15
135	A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	15
136	An ortho-Iminoquinone Compound Reacts with Lysine Inhibiting Aggregation while Remodeling Mature Amyloid Fibrils. ACS Chemical Neuroscience, 2017, 8, 1704-1712.	3.5	14
137	Pharmacological activation of ATF6 remodels the proteostasis network to rescue pathogenic GABAA receptors. Cell and Bioscience, 2022, 12, 48.	4.8	14
138	A designed protein binding-pocket to control excited-state intramolecular proton transfer fluorescence. Organic and Biomolecular Chemistry, 2019, 17, 1076-1080.	2.8	13
139	Stereoelectronic effects in stabilizing proteinâ€“N-glycan interactions revealed by experiment and machine learning. Nature Chemistry, 2021, 13, 480-487.	13.6	13
140	Modulating protein quality control. ELife, 2016, 5, .	6.0	12
141	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage. ACS Medicinal Chemistry Letters, 2020, 11, 1973-1979.	2.8	12
142	Does protein aggregation drive postmitotic tissue degeneration?. Science Translational Medicine, 2021, 13, .	12.4	12
143	Immunoprecipitation of Amyloid Fibrils by the Use of an Antibody that Recognizes a Generic Epitope Common to Amyloid Fibrils. PLoS ONE, 2014, 9, e105433.	2.5	11
144	Inverse Drug Discovery identifies weak electrophiles affording protein conjugates. Current Opinion in Chemical Biology, 2022, 67, 102113.	6.1	10

#	Article	IF	Citations
145	Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. Biochemistry, 2020, 59, 1800-1803.	2.5	9
146	Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato, 2021, 2, 645-659.	0.6	9
147	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3441-3449.	2.2	8
148	Mispacking of the Phe87 Side Chain Reduces the Kinetic Stability of Human Transthyretin. Biochemistry, 2018, 57, 6919-6922.	2.5	8
149	Hsp104 Gives Clients the Individual Attention They Need. Cell, 2012, 151, 695-697.	28.9	7
150	Mechanism of Action of the Cytotoxic Asmarine Alkaloids. ACS Chemical Biology, 2018, 13, 1299-1306.	3.4	5
151	Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. Bioorganic and Medicinal Chemistry Letters, 2022, 60, 128571.	2.2	5
152	Chaperonins Resculpt Folding Free Energy Landscapes to Avoid Kinetic Traps and Accelerate Protein Folding. Journal of Molecular Biology, 2014, 426, 2736-2738.	4.2	4
153	ATF6 Activation Reduces Amyloidogenic Transthyretin Secretion through Increased Interactions with Endoplasmic Reticulum Proteostasis Factors. Cells, 2022, 11, 1661.	4.1	4
154	The two shapes of the Tau protein. ELife, 2018, 7, .	6.0	3
155	Response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 140-141.	3.0	1
156	From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy. , 2021, , 65-103.		1
157	Proteostasis Modulation Prevents Photoreceptor Pathology in Retinal Organoids. SSRN Electronic Journal, 0, , .	0.4	1
158	Examining the structural and functional roles of the ?-turn region in neuropeptide Y. International Journal of Peptide Research and Therapeutics, 1996, 3, 133-142.	0.1	0
159	Structure-Based Design, Synthesis and Evaluation of Amyloid Fibril Inhibitors. Biochemical Society Transactions, 2000, 28, A51-A51.	3.4	0
160	Therapeutic Strategies Against Gain and Loss of Function Misfolding Diseases. FASEB Journal, 2006, 20, A850.	0.5	0
161	Determinants for dephosphorylation of the RNA polymerase II Câ€terminal domain by Scp1. FASEB Journal, 2007, 21, A1032.	0.5	0
162	Adapting the Chemistry and/or Biology of Proteostasis to Ameliorate Protein Aggregation Diseases. FASEB Journal, 2018, 32, 247.2.	0.5	0